Clever Culture Systems AG
About Clever Culture Systems AG
Clever Culture Systems AG is a pioneering healthcare AI company specializing in intelligent automation solutions for microbiology laboratories. The company’s flagship product, the APAS® Independence, is an FDA-cleared and CE-marked in vitro diagnostic instrument that leverages artificial intelligence and machine learning to automate the imaging, analysis, and interpretation of agar culture plates. This technology is designed by microbiologists for microbiologists, aiming to seamlessly integrate into existing laboratory workflows and address critical challenges such as resource constraints, manual processing bottlenecks, and the need for consistent, accurate results.
For physicians, the APAS Independence offers significant benefits by streamlining the microbiology workflow, particularly in areas like urine cultures, infection control (e.g., MRSA and VRE screening), and antimicrobial susceptibility testing. By automatically screening and triaging culture plates, the system can identify negative or non-significant growth plates, allowing microbiologists to focus their expertise on positive and significant growth plates that require more complex analysis. This not only accelerates patient diagnosis and turnaround times but also improves the overall efficiency and quality of results, enhancing data integrity and traceability in both clinical and pharmaceutical microbiology settings.
Focus Areas
Business Intelligence
| Key Investors | Hettich AG (former joint venture partner and current shareholder), LBT Innovations (original developer, now rebranded as Clever Culture Systems) |
| Partnerships | Thermo Fisher Scientific (exclusive US distributor for clinical customers and selected European countries), AstraZeneca, Bristol Myers Squibb, Novo Nordisk (pharmaceutical manufacturing customers) |
| Acquisitions | LBT Innovations Limited acquired the remaining 50% shareholding of the Clever Culture Systems joint venture from Hettich in December 2021. Subsequently, LBT Innovations Limited rebranded and changed its name to Clever Culture Systems. |
| Technology | Automated Plate Assessment System (APAS® Independence), AI and machine learning software, intelligent imaging platform technology, modular automation solutions, cloud-native (implied by data integrity and traceability features) |
| FDA Clearances | At least 1 (APAS Independence instrument and associated urine analysis module, cleared as a Class II medical device), with multiple global regulatory clearances (FDA, CE Mark, TGA). cleared products (estimated) |
What Physicians Need to Know
For physicians, Clever Culture Systems AG's technology, particularly the APASu00ae Independence, offers significant advantages by accelerating the diagnostic process. The automated plate reading and interpretation capabilities lead to faster turnaround times for microbiology results, enabling quicker patient isolation and initiation of appropriate treatment for infectious diseases. The AI-driven analysis enhances accuracy and consistency, reducing the variability associated with manual plate reading and providing more reliable diagnostic information. This improved efficiency allows microbiologists to focus their expertise on complex, significant cases, ultimately contributing to better patient outcomes and more effective infection control strategies.
The APASu00ae Independence is designed for seamless integration into existing laboratory workflows. It offers full integration with Laboratory Information Management Systems (LIMS) for real-time reporting and contemporaneous data capture. The system is compatible with various culture media, including split plates, and does not require proprietary media, minimizing disruption and avoiding the need for extensive laboratory remodeling.
Reviews & Opinions
Videos
News, demos, and interviews about Clever Culture Systems AG.
Videos load interactively. If none appear, search YouTube for Clever Culture Systems AG →
Press & Coverage
Frequently Asked Questions
Related Companies
Google DeepMind is a leading artificial intelligence (AI) research laboratory, a subsidiary of Alphabet Inc., dedicated to developing advanced AI systems to benefit humanity. The company focuses on creating general-purpose AI that can learn and solve complex problems, drawing inspiration from neuroscience and machine learning. Their work spans various fields, including healthcare, scientific discovery, and […]
Tempus AI is a leading health technology company that leverages artificial intelligence (AI) and machine learning to advance precision medicine. Founded in 2015 by Eric Lefkofsky, the company was inspired by the need for more data-driven approaches in oncology care. Tempus has since built one of the world’s largest libraries of multimodal clinical and molecular […]
LabLynx is a privately held American laboratory informatics company that specializes in developing, supporting, and marketing Laboratory Information Management System (LIMS) solutions. The company has a long history in the industry, having introduced one of the first browser-based LIMS products in 1997. LabLynx’s primary offerings include ELab LIMS, a configurable cloud-based LIMS that serves various […]
August AI is a healthcare artificial intelligence company that has developed an AI-powered digital health companion. This platform is designed to provide accessible medical care and health guidance, acting as a ‘health companion’ rather than a replacement for clinical visits. It assists users in understanding symptoms, interpreting medical reports, and managing ongoing treatment. The company’s […]
Allergios® is a healthcare AI company focused on revolutionizing allergy diagnostics. The company has developed a method and system, based on research from the University of Bremen and Medical University of Vienna, that directly diagnoses allergies by visualizing the allergic response. Their solution involves an in-vitro allergy diagnostic that analyzes how patient blood serum induces […]
aisencia GmbH is a healthcare AI company focused on revolutionizing diagnostic workflows in dermatopathology through artificial intelligence. They develop digital, AI-powered software solutions like Vistaneos and Cutaneos 80, designed to streamline pathology processes for faster, more precise, and accessible cancer diagnoses. The company’s technology aims to classify over 50 types of skin lesions, covering approximately […]